Crystalys Therapeutics
PrivateLast Round
Series A
Sep 30, 2025
Total Funding Raised
$205M
Company Overview
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation URAT1 inhibitor, as a second-line therapy for gout.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crystalys Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Crystalys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 30, 2025 |
Crystalys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prebys Ventures Impact Fund | Series A |
| Wedbush Healthcare Partners | Series A |
| KB Investment | Series A |
| Lightstone Ventures | Series A |
| abrdn Inc. | Series A |
| Pontifax Venture Capital | Series A |
| Perceptive Xontogeny Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 11, 2026
Tim Walbert appointed as Independent Director.
- Jan 21, 2026
Justin Thacker appointed as new CFO to support Phase 3 trials.
Crystalys Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Crystalys Therapeutics's valuation, stock price, and market status.
